# Novo and Lilly Reduce Prices of Weight-Loss Drugs in China - Meyka

## Metadata
| Field | Value |
|-------|-------|
| Source | Meyka |
| URL | https://news.google.com/rss/articles/CBMiigFBVV95cUxOZWp2TG1SMGh0Y2t6cDdwdFJhZ3dxT2lIVExVMjFfTFZrR3lMOElqaUc3NkZfSXE3TUNzc1ViLS11WUpkWVNHMnZRQVU0RkdrT1RsWmp2V0kxMW0xREtUY0wzTnZKNHg0NWlpS0tfazFkUl9Kd2dHWGdhSVRVSk5HRDdFVjBLZko0Tmc?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-30 12:05 |
| Category | GLP-1 |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Novo Nordisk and Eli Lilly are reducing prices of weight-loss drugs in China, signaling strategic market expansion and competitive dynamics in the GLP-1 obesity treatment market.

## Key Entities
Novo Nordisk, Eli Lilly

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
